Google
Trusted Resources: News & Events
Latest announcements and gatherings
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease
Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.
If approved, Endari would be the first FDA-approved treatment for pediatric patients with SCD, and the first new treatment in almost 20 years for adult patients. The therapy is an orally-administered pharmaceutical grade L-glutamine.
The FDA is not bound by the Committee’s recommendation, but takes its advice into consideration when reviewing New Drug Applications. Endari has received Orphan Drug designation in the U.S., Orphan Medicinal Product designation in the EU and Fast Track designation from the FDA.
+myBinderRelated Content
-
What it’s like to be 17 and living with sickle cell diseaseTre Adegoroye is 17 and was diagnosed wi...
-
HydroxyureaHydroxyurea (Hydrea) is used alone or wi...
-
Phase 3 study of L-Glutamine in sickle cell disease: Analyses of time to first and second crisis and average cumulat...A Phase 3, double-blind, randomized, pla...
-
In France, Boy Becomes First Sickle Cell Disease Patient to be Treated With Gene TherapyA 13-year-old boy with sickle cell disea...
-
Family Celebrates 7-Year-Old’s Sickle Cell Cure Thanks to Sister’s Life-Saving GiftOne 7-year-old who suffered his whole li...
-
Marijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.